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SUMMARY  &  CONCLUSIONS
Chronic Kidney Disease (CKD) affects approximately 1 in 10
Americans. Diabetic nephropathy is also associated with the
development of chronic kidney disease-­mineral bone disorder
(CKD-­MBD). CKD-­MBD disrupts the normal bone-­kidney
endocrine axis responsible for regulating mineral metabolism,
and hyperphosphatemia develops in late stage disease.
Important clinical hallmarks of the CKD-­MBD progression
include elevated bioactive Fibroblast growth factor-­23 (FGF23)
and suppression of FGF23’s co-­receptor, αKlotho (αKL). In
healthy individuals the hormone FGF23, primarily produced by
bone, and aKL aid in maintaining normal phosphate and vitamin
D homeostasis. It is currently unknown what drives the
suppression of αKL expression, however increasing αKL
expression in CKD-­MBD models is being investigated as a novel
therapeutic. Our study sought to develop a novel in vitro model
of one of the clinical hallmarks of the progression of CKD-­MBD,
αKL suppression, to investigate both possible stimuli of its
repression and downstream signaling events. The Human
Embryonic Kidney (HEK) cell line was used to determine if
changes in fluid shear stress, similar to those that occur in
diabetic nephropathy, could lead to reduced αKL expression.
HEK cells were plated and exposed to oscillatory fluid shear
stress (OFSS) for intervals between 0-­60 min to examine protein
expression or 0-­2 hours to assess gene expression. HEK cells
were sensitive to mechanical stimulation as pathways including
increased ERK phosphorylation occurred in response to OFSS.
In response to longer bouts of OFSS αKL expression was
significantly (p<0.05) reduced. Dramatic changes in fluid shear
stress may serve as a stimulus for reduced αKL expression in
CKD-­MBD. Further studies are underway to investigate
downstream signaling events related to αKL suppression.
Understanding both the stimuli of αKL suppression and related
downstream signaling events could provide novel therapeutic
targets for the treatment of CKD-­MBD.
• Western  blot  showed  increased  ERK  
phosphorylation  occurred  in  response  to  fluid  
shear  stress
• qPCR  demonstrated  a  significant  decrease  in  
αKL  gene  expression  after  2  hours  of  fluid  stress  
and  a  pattern  of  decreased  gene  expression  after  
1  hour
• Shear  stress  showed  significant  gene  expression  
and  changes  in  αKL  matching  those  seen  in  
CKD-­MBD
• These  preliminary  findings  show  trends  
consistent  with  a  novel  in  vitro  model  of  CKD-­
MBD  with  decreases  in  αKL  expression
• Repeat  Western  blot  and  qPCR  experiments  
• Repeat  experiment  in  HK-­2  (proximal  tubule)  
cell  line
• Examine  expression  levels  of  more  signaling  
molecules  to  confirm  other  changes  seen  in  
CKD-­MBD
FUTURE  DIRECTIONS
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BACKGROUND
Oscillatory fluid sheer stress serves as a
stimuli for reduced αKlotho expression in
kidney cells.
HEK  cells  are  responsive  to  OFSS  stimulation
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Figure 1. A) HEK cells were exposed to either static or OFFS conditions (15 min or 30 min)
and harvested immediately for protein analysis. Western blot analysis was run to examine
p-­Erk and total Erk. B) The software program ImageJ was used to quantify p-­Erk and total
Erk (*p<0.05).
Figure 2. HEK cells were exposed to either static or OFFS conditions (1 or 2 hrs) and
harvested the next day. qPCR analysis was performed examining Klotho expression and
Actin (*p<0.05).
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• Approximately  1:10  Americans  have  CKD-­MBD
• CKD-­MBD  disrupts  the  normal  bone-­kidney  endocrine  axis  
and  hyperphosphatemia  develops  in  late  stage  disease
• Important  clinical  hallmarks  of  the  CKD-­MBD  progression  
include  elevated  bioactive  Fibroblast  growth  factor-­23  
(FGF23)  and  suppression  of  FGF23’s  co-­receptor,  αKlotho  
(αKL)
• FGF23  and  aKL aid  in  maintaining  normal  phosphate  and  
vitamin  D  homeostasis.
• It  is  currently  unknown  what  drives  the  suppression  of  αKL  
expression,  however  increasing  αKL  expression  in  CKD-­
MBD  models  is  being  investigated  as  a  novel  therapeutic.
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